| RMD |
Report |
Net Revenue (Q4 FY2026) |
BEAT |
pred ~$1,475M vs. cons $1,460M |
MEDIUM |
| RMD |
Report |
Non-GAAP Gross Margin (Q4 FY2026) |
BEAT |
pred ~63.2% vs. cons ~62.7% |
MEDIUM |
| RMD |
Report |
Non-GAAP Diluted EPS (Q4 FY2026) |
BEAT |
pred ~$2.97 vs. cons $2.89 |
MEDIUM |
| RMD |
Guide |
FY2027 Revenue (FY2027) |
BETTER |
guide ~$5,950-6,050M vs. cons $5,942M |
MEDIUM |
| RMD |
Guide |
FY2027 Non-GAAP EPS (FY2027) |
BETTER |
guide ~$12.20-12.40 vs. cons $12.07 |
MEDIUM |
| RMD |
Guide |
Non-GAAP Gross Margin (FY2027) |
BETTER |
guide 63-64% vs. cons ~62.6% implied |
MEDIUM |
| RMD |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| RMD |
Return |
5-day cumulative residual |
+4.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH - sell-side revises FY2027 EPS up on MatrixCare-adjusted organic growth clarity; short covering adds bid |
MEDIUM |